LOVELAND, Colo., Dec. 9, 2013 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA, "Heska"), the leading provider of serum IgE testing for companion animals, announced today a new breakthrough in this growing animal health category.
"Heska scientists have significantly improved the sensitivity of IgE detection afforded by our proprietary ALLERCEPT® technology," commented Michael McGinley, Heska's President of Pharmaceuticals and Biologicals. "This new, unprecedented level of sensitivity, coupled with our gold standard specificity, provides veterinary practitioners with an extraordinary new tool for identifying the precise allergens to which their patients are hypersensitive."
Allergy-related symptoms are among the top reasons for dogs and cats to see a veterinarian. While the majority of these conditions are rarely life threatening, they can become a chronic and serious concern.
"As the innovators of serum allergy testing in the veterinary industry, Heska provides veterinarians with an accurate, easy, cost-effective testing solution for pets, the results of which are then used for customized immunotherapy treatment," added Nancy Wisnewski, Heska's Executive Vice President, Product Development & Customer Support. "Following our successful launch of sublingual ALLERCEPT® Therapy Drops in 2012, Heska has continued to invest in the advancement of our new allergen-specific IgE test platform."
The market-leading ALLERCEPT Definitive Allergen Panel Test has been fully re-engineered to take advantage of the new detection technology and an expanded, comprehensive allergen panel. This new combination of increased sensitivity with outstanding specificity streamlines effective testing and treatment solutions for veterinarians and pet owners. The enhanced test, along with the new allergen panels and test reports, will be available in early 2014.
About Heska Heska Corporation (NASDAQ: HSKA - News) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.
This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. These include uncertainties related to the success of incorporating scientific advancements into products; risks related to the commercial success of any anticipated new product; uncertainties related to the launch time of any new product; uncertainties related to the technical performance of any new product; uncertainties related to the perception of Heska's products and technology by Heska's customers and potential customers; uncertainties related to the perception a veterinarian, scientist or any other person or group of persons would have related to the impact of new scientific knowledge; competition and the impact of new products others may introduce; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.
SOURCE Heska Corporation